08D Stock Overview
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Mirum Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.40 |
| 52 Week High | US$31.60 |
| 52 Week Low | US$21.80 |
| Beta | 1.14 |
| 1 Month Change | -2.61% |
| 3 Month Change | -5.88% |
| 1 Year Change | -3.45% |
| 3 Year Change | 46.06% |
| 5 Year Change | n/a |
| Change since IPO | 41.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| 08D | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.8% | 0.7% | 2.0% |
| 1Y | -3.4% | -24.4% | 2.0% |
Return vs Industry: 08D exceeded the German Biotechs industry which returned -22.8% over the past year.
Return vs Market: 08D underperformed the German Market which returned 1.3% over the past year.
Price Volatility
| 08D volatility | |
|---|---|
| 08D Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 08D has not had significant price volatility in the past 3 months.
Volatility Over Time: 08D's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 264 | Chris Peetz | www.mirumpharma.com |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis.
Mirum Pharmaceuticals, Inc. Fundamentals Summary
| 08D fundamental statistics | |
|---|---|
| Market cap | €1.08b |
| Earnings (TTM) | -€152.76m |
| Revenue (TTM) | €174.22m |
6.2x
P/S Ratio-7.0x
P/E RatioIs 08D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 08D income statement (TTM) | |
|---|---|
| Revenue | US$186.37m |
| Cost of Revenue | US$47.04m |
| Gross Profit | US$139.34m |
| Other Expenses | US$302.75m |
| Earnings | -US$163.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.48 |
| Gross Margin | 74.76% |
| Net Profit Margin | -87.68% |
| Debt/Equity Ratio | 123.2% |
How did 08D perform over the long term?
See historical performance and comparison